Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 5/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040706 | 0.82 | AMY1A (0.57) | AMY1ASLC2A1NPC1RAB9AALDH1A1 | |
| SCHEMBL20125069 | 0.81 | AMY1A (0.63) | AMY1ASLC2A1NPC1RAB9AALDH1A1 | |
| SCHEMBL15643913 | 0.81 | SMN1; SMN2 (0.64) | AMY1ASLC2A1NPC1RAB9AALDH1A1 | |
| SCHEMBL2090887 | 0.81 | AMY1A (0.63) | AMY1ASLC2A1NPC1RAB9AALDH1A1 | |
| SCHEMBL3332738 | 0.80 | AMY1A (0.67) | AMY1ASLC2A1NPC1RAB9AALDH1A1 | |
| SCHEMBL2096956 | 0.79 | AMY1A (0.76) | AMY1ASLC2A1NPC1RAB9AALDH1A1 | |
| SCHEMBL31027930 | 0.79 | AMY1A (0.76) | AMY1ASLC2A1NPC1RAB9AALDH1A1 | |
| SCHEMBL15829537 | 0.78 | AMY1A (0.59) | AMY1ASLC2A1NPC1RAB9AALDH1A1 | |
| SCHEMBL856385 | 0.76 | NPC1 (0.69) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL27072943 | 0.75 | AMY1A (0.59) | AMY1ASLC2A1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524873-B2 | Substituted N-phenylmethyl ethanamines; N-((6-(methyloxy)-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl)methyl)-1-(1-naphthalenyl)ethanamine; parathyroid hormone inhibitors; antisecretory agents; osteoporosis | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070142381-A1 | Calcium receptor modulating agents | AMGEN INC. | 2007-06-21 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082625-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | AMY1A 4090/4885SLC2A1 2654/4885NPC1 2679/4885 |
| US-20070142381-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | AMY1A 4489/4885SLC2A1 2621/4885NPC1 2793/4885 |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | PTH1R, PTMS, SOST | AMY1A 2005/4885SLC2A1 2340/4885NPC1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.